AstraZeneca Sues Aurobindo to Protect Nexium 24HR Patents

AstraZeneca has filed a suit against Aurobindo over Nexium, alleging infringement of two patents for its heartburn therapy Nexium 24HR.

The drugmaker is asking the court to order Aurobindo not to sell a generic version of the drug — which currently is under review by the FDA — until the two patents expire on May 25, 2018.

The suit, filed in the U.S. District Court for the District of New Jersey, states that Aurobindo filed its ANDA on the grounds that the patents are either invalid, unenforceable or would not be infringed.